Table 2. Baseline characteristics comparison between R-CHOP (n=57) and da-R-EPOCH (n=24) cohorts.
| Events | R-CHOP (n=57), n | da-R-EPOCH (n=24), n | P value | Test method |
|---|---|---|---|---|
| Age (years) | <0.001 | Chi-squared | ||
| ≥60 | 47 | 10 | ||
| <60 | 10 | 14 | ||
| Gender | 0.81 | Chi-squared | ||
| Male | 34 | 15 | ||
| Female | 23 | 9 | ||
| IPI scores | ||||
| High IPI scores | 9 | 3 | >0.99 | Fisher’s exact |
| Intermediate IPI scores | 32 | 13 | 0.87 | Chi-squared |
| Low IPI scores | 16 | 8 | 0.63 | Chi-squared |
| LDH | 0.43 | Chi-squared | ||
| With increased LDH | 12 | 7 | ||
| Without increased LDH | 45 | 17 | ||
| HD-MTX | 0.33 | Fisher’s exact | ||
| With HD-MTX | 8 | 6 | ||
| Without HD-MTX | 49 | 18 | ||
| ECOG PS | ||||
| ≥2 | 11 | 4 | >0.99 | Fisher’s exact |
| <2 | 46 | 20 |
P values derived from Chi-squared or Fisher’s exact test as appropriate. da-R-EPOCH, dose adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HD-MTX, high-dose methotrexate; IPI, International Prognostic Index; LDH, lactate dehydrogenase; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.